摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(3,3,3-trifluoropropyl)magnesium bromide | 461-20-1

中文名称
——
中文别名
——
英文名称
(3,3,3-trifluoropropyl)magnesium bromide
英文别名
3,3,3-trifluoropropyl magnesium bromide;(3,3,3-trifluoro-propyl)-magnesium bromide;1,1,1-trifluoropropanylmagnesium bromide
(3,3,3-trifluoropropyl)magnesium bromide化学式
CAS
461-20-1
化学式
C3H4BrF3Mg
mdl
——
分子量
201.269
InChiKey
PAVBFVDIWOBMCX-UHFFFAOYSA-M
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.37
  • 重原子数:
    8.0
  • 可旋转键数:
    2.0
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    0.0
  • 氢给体数:
    0.0
  • 氢受体数:
    0.0

SDS

SDS:a2cca01822f2d39df6a5b4b3343994d3
查看

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS<br/>[FR] COMPOSÉS D'HÉTÉROARYLE BICYCLIQUES SUBSTITUÉS
    申请人:BRISTOL MYERS SQUIBB CO
    公开号:WO2013049263A1
    公开(公告)日:2013-04-04
    Disclosed are azaindazole compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein: X is O and Y is N; or X is S and Y is CH; Z is CR2 or N; Q is a heteroaryl; and R1 is defined herein. Also disclosed are methods of using such compounds in the treatment of at least one CYP17 associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.
    披露了公式(I)的氮杂吲唑化合物:或其药用可接受盐,其中:X是O且Y是N;或者X是S且Y是CH;Z是CR2或N;Q是杂芳基;R1如本文所定义。还披露了使用这些化合物治疗至少一种与CYP17相关的病症的方法,例如,癌症,以及包含这些化合物的药物组合物。
  • [EN] BENZIMIDAZOLONE DERIVATIVES AS BROMODOMAIN INHIBITORS<br/>[FR] DÉRIVÉS DE BENZIMIDAZOLONE EN TANT QU'INHIBITEURS DE BROMODOMAINE
    申请人:GILEAD SCIENCES INC
    公开号:WO2014160873A1
    公开(公告)日:2014-10-02
    This application relates to chemical compounds which may act as inhibitors of, or which may otherwise modulate the activity of, a bromodomain-containing protein, including bromodomain-containing protein 4 (BRD4), and to compositions and formulations containing such compounds, and methods of using and making such compounds. Compounds include compounds of Formula (I) wherein R1a, R1b, R2a, R2b, R3, and X are described herein.
    这个应用涉及可能作为结构域含蛋白质的抑制剂或以其他方式调节其活性的化合物,包括结构域含蛋白质4(BRD4),以及含有这些化合物的组合物和配方,以及使用和制备这些化合物的方法。化合物包括式(I)中描述的化合物,其中R1a、R1b、R2a、R2b、R3和X如本文所述。
  • MOLECULES HAVING PESTICIDAL UTILITY, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES, RELATED THERETO
    申请人:Dow AgroSciences LLC
    公开号:US20170208803A1
    公开(公告)日:2017-07-27
    This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda, processes to produce such molecules, intermediates used in such processes, compositions containing such molecules, and processes of using such molecules and compositions against such pests. These molecules and compositions may be used, for example, as acaricides, insecticides, miticides, molluscicides, and nematicides. This document discloses molecules having the following formula (“Formula One”).
    这份披露涉及具有对节肢动物门、软体动物门和线虫门害虫具有杀虫效用的分子领域,用于生产这种分子的过程,用于这种过程的中间体,含有这种分子的组合物,以及使用这种分子和组合物对抗这些害虫的过程。这些分子和组合物可以用作杀螨剂杀虫剂杀螨剂、杀软体动物剂和杀线虫剂。本文件披露了具有以下式(“式一”)的分子。
  • [EN] ARTEMISININ-BASED PEROXIDE COMPOUNDS AS BROAD SPECTRUM ANTI-INFECTIVE AGENTS<br/>[FR] COMPOSES DE PEROXYDE A BASE D'ARTEMISININE TENANT LIEU D'AGENTS ANTI-INFECTIEUX A LARGE SPECTRE
    申请人:UNIV MISSISSIPI
    公开号:WO2003095444A1
    公开(公告)日:2003-11-20
    Described herein is the synthesis, bioassay results and utility of new C-9 and C-10 substituted artemisinin derivatives with easily functionalizable groups attached to the artemisinin skeleton through carbon chain or heteroatoms. Described also is the demonstration of this class of compounds for their broad-spectrum anti-parasitic activity. Certain of these analogs possess noticeable cytotoxicity deliberately focused on treatment of cancerous diseases.
    本文描述了合成、生物测定结果以及新的C-9和C-10取代青蒿素生物的用途,这些衍生物具有易于功能化的基团,通过碳链或杂原子连接到青蒿素骨架上。同时还展示了这类化合物在广谱抗寄生虫活性方面的表现。其中一些类似物具有明显的细胞毒性,专门用于治疗癌症性疾病。
  • 페닐피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 글루카곤 수용체 활성 관련 질환의 예방 또는 치료용 약학적 조성물
    申请人:Gachon University of Industry-Academic cooperation Foundation 가천대학교 산학협력단(220040376324) BRN ▼129-82-07687
    公开号:KR20200021741A
    公开(公告)日:2020-03-02
    페닐피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 글루카곤 수용체 활성 관련 질환의 예방 또는 치료용 약학적 조성물에 관한 것으로, 상기 페닐피리미딘 유도체는 cAMP 또는 글루카곤 생성 저해 효과가 우수하여 GCGR 활성 저해 효과를 나타내고, 우수한 혈당 강하 효과를 나타냄을 in vitro 뿐만 아니라 in vivo에서도 확인하였으며, 세포 독성이 낮아, 안전성이 검증된 바, GCGR 활성 관련 질환인 대사성 질환 특히, 당뇨의 치료에 유용하게 사용될 수 있다.
    苯基吡啶衍生物,其制备方法以及含有其作为有效成分的葡萄糖素受体活性相关疾病的预防或治疗药物组合物,所述苯基吡啶衍生物对cAMP葡萄糖素生成具有出色的抑制效果,表现出优越的GCGR活性抑制效果,并且在体外和体内均已确认其出色的降血糖效果,细胞毒性低,安全性得到验证,可用于治疗与GCGR活性相关的代谢性疾病,特别是糖尿病的治疗。
查看更多